Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria

Spangler, S K; Jacobs, Michael; Appelbaum, Peter C.

doi:10.1128/aac.38.11.2599

Cited by 24 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1988 44 Cefaclor1016–>32>32>32Spangler et al . 1994 45 1232–>6464>64Bauernfeind 1991 46 36—32–12832–>100Thornsberry 1992 42 Cefprozil36—4 a 4–8 a Thornsberry 1992 42 1264–>6464>64Bauernfeind 1991 46 Cefuroxime262–>128>128>128Pierard et al . 1989 43 1016–>32>32>32Spangler et al .…”

Section: Are All Cephalosporins the Same With Regard To CDI Risk?unclassified

See 1 more Smart Citation

Role of cephalosporins in the era ofClostridium difficileinfection

Wilcox

Chalmers

Nord

et al. 2016

J. Antimicrob. Chemother.

View full text Add to dashboard Cite

The incidence of Clostridium difficile infection (CDI) in Europe has increased markedly since 2000. Previous meta-analyses have suggested a strong association between cephalosporin use and CDI, and many national programmes on CDI control have focused on reducing cephalosporin usage. Despite reductions in cephalosporin use, however, rates of CDI have continued to rise. This review examines the potential association of CDI with cephalosporins, and considers other factors that influence CDI risk. EUCLID (the EUropean, multicentre, prospective biannual point prevalence study of CLostridium difficile Infection in hospitalized patients with Diarrhoea) reported an increase in the annual incidence of CDI from 6.6 to 7.3 cases per 10 000 patient bed-days from 2011–12 to 2012–13, respectively. While CDI incidence and cephalosporin usage varied widely across countries studied, there was no clear association between overall cephalosporin prescribing (or the use of any particular cephalosporin) and CDI incidence. Moreover, variations in the pharmacokinetic and pharmacodynamic properties of cephalosporins of the same generation make categorization by generation insufficient for predicting impact on gut microbiota. A multitude of additional factors can affect the risk of CDI. Antibiotic choice is an important consideration; however, CDI risk is associated with a range of antibiotic classes. Prescription of multiple antibiotics and a long duration of treatment are key risk factors for CDI, and risk also differs across patient populations. We propose that all of these are factors that should be taken into account when selecting an antibiotic, rather than focusing on the exclusion of individual drug classes.

show abstract

Section: Are All Cephalosporins the Same With Regard To CDI Risk?unclassified

“…1989 43 1016–>32>32>32Spangler et al . 1994 45 1264–>64>64>64Bauernfeind 1991 46 7364–≥256≥256≥256Chow et al . 1985 47 401>256 b ——Noren et al .…”

Section: Are All Cephalosporins the Same With Regard To CDI Risk?unclassified

Role of cephalosporins in the era ofClostridium difficileinfection

Wilcox

Chalmers

Nord

et al. 2016

J. Antimicrob. Chemother.

View full text Add to dashboard Cite

show abstract

“…Penicillinase-producing strains of F. nucleatum have been isolated (112,125,294), and isolation of ␤-lactamase-producing strains of fusobacteria is increasing (142). As ␤-lactamase production and ␤-lactam resistance have been increasingly found in gram-negative bacteria, including F. nucleatum, the susceptibility of different bacteria to new agents has been tested (7,270). Biapenem, imipenem, the penem WY-49605, and trospectomycin were active against F. nucleatum in vitro, as were the commonly used agents chloramphenicol and metronidazole.…”

Section: Susceptibility To Antibioticsmentioning

confidence: 99%

Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum.

Bolstad

Jensen

Bakken

1996

Clinical Microbiology Reviews

116

147

View full text Add to dashboard Cite

“…No strains of resistant Peptostreptococcus (19 strains tested) were seen in that study. Strains of C. difficile with moderately high MICs have been found (MIC 50 of 4 g/ml and MIC 90 of 8 g/ml [15,18]). MICs for Peptostreptococcus were Յ2 g/ml, and the MIC 90 was 1 g/ml (15).…”

mentioning

confidence: 99%

In Vitro Activities of Faropenem against 579 Strains of Anaerobic Bacteria

Wexler

Molitoris

John

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The activity of faropenem, a new oral penem, was tested against 579 strains of anaerobic bacteria by using the NCCLS-approved reference method. Drugs tested included amoxicillin-clavulanate, cefoxitin, clindamycin, faropenem, imipenem, and metronidazole. Of the 176 strains of Bacteroides fragilis group isolates tested, two isolates had faropenem MICs of 64 g/ml and imipenem MICs of >32 g/ml. Faropenem had an MIC of 16 g/ml for an additional isolate of B. fragilis; this strain was sensitive to imipenem (MIC of 1 g/ml). Both faropenem and imipenem had MICs of <4 g/ml for all isolates of Bacteroides capillosus (10 isolates), Bacteroides splanchnicus (13 isolates), Bacteroides ureolyticus (11 isolates), Bilophila wadsworthia (11 isolates), Porphyromonas species (42 isolates), Prevotella species (78 isolates), Campylobacter species (25 isolates), Sutterella wadsworthensis (11 isolates), Fusobacterium nucleatum (19 isolates), Fusobacterium mortiferum/varium (20 isolates), and other Fusobacterium species (9 isolates). Faropenem and imipenem had MICs of 16 to 32 g/ml for two strains of Clostridium difficile; the MICs for all other strains of Clostridium tested (69 isolates) were <4 g/ml. Faropenem had MICs of 8 and 16 g/ml, respectively, for two strains of Peptostreptococcus anaerobius (MICs of imipenem were 2 g/ml). MICs were <4 g/ml for all other strains of gram-positive anaerobic cocci (53 isolates) and non-spore-forming gram-positive rods (28 isolates). Other results were as expected and reported in previous studies. No metronidazole resistance was seen in gram-negative anaerobes other than S. wadsworthensis (18% resistant); 63% of gram-positive non-spore-forming rods were resistant. Some degree of clindamycin resistance was seen in most of the groups tested.Resistance in anaerobic bacteria to all classes of antimicrobial agents is an increasing problem. ␤-Lactam resistance is generally due to the production of ␤-lactamases, and carbapenem resistance is generally due to metallo-␤-lactamase enzymes that hydrolyze the antimicrobial agent (1, 3). Faropenem, a new oral penem antibiotic, is highly stable to a number of ␤-lactamases produced by clinical isolates. Faropenem had significant activity against the common respiratory pathogens Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis and poor activity against Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Enterococcus faecium (18). This study was designed to evaluate the activity of faropenem, an oral penem antibiotic, against a wide range of clinically significant anaerobic bacteria.The bacteria included in this study were recent clinical isolates from the Greater Los Angeles VA Healthcare Center. Bacteria were identified according to established procedures (5). MICs were determined by the NCCLS-approved Wadsworth agar dilution technique using 10 5 CFU/spot of inoculation and Brucella base-laked blood agar (6). Plates were incubated in an anaerobic chamber (Anaerobe Systems, San Jose, Calif.) for 48 h at 37°C. MICs were defined as ...

show abstract

Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria

Cited by 24 publications

References 16 publications

Role of cephalosporins in the era ofClostridium difficileinfection

Role of cephalosporins in the era ofClostridium difficileinfection

Taxonomy, biology, and periodontal aspects of Fusobacterium nucleatum.

In Vitro Activities of Faropenem against 579 Strains of Anaerobic Bacteria

Contact Info

Product

Resources

About